2e6550a8-fbe0-4b31-bb3a-4d7e93709126
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 84.9144421629021
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- CHOLESTEROL_HOMEOSTASIS+0.390
- HEDGEHOG_SIGNALING+0.340
- SPERMATOGENESIS+0.300
- APICAL_SURFACE+0.280
- PROTEIN_SECRETION+0.250
- COAGULATION+0.240
- G2M_CHECKPOINT+0.220
- MYOGENESIS+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- MYC_TARGETS_V2-0.430
- OXIDATIVE_PHOSPHORYLATION-0.410
- INTERFERON_GAMMA_RESPONSE-0.360
- ALLOGRAFT_REJECTION-0.280
- MYC_TARGETS_V1-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- FATTY_ACID_METABOLISM-0.230
- XENOBIOTIC_METABOLISM-0.210
- DNA_REPAIR-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.751 |
| 2 | TCGA-BL-A13J-01A-11R-A10U-07 | — | — | 0.745 |
| 3 | DRR168609 | — | — | 0.744 |
| 4 | TCGA-P6-A5OF-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.739 |
| 5 | 4b3022ba-0232-493c-b3fc-2447e8cf7113 | — | — | 0.728 |
| 6 | TCGA-D8-A27H-01A-11R-A16F-07 | — | E | 0.726 |
| 7 | 34a7b3e9-caae-48d1-97a4-2bcb00fa2383 | — | — | 0.718 |
| 8 | SRR4195679 | — | — | 0.715 |
| 9 | 20040086.TNBC | — | C | 0.712 |
| 10 | 21b172a2-72ce-4cfc-b021-cf8c36359feb | — | — | 0.709 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.390 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |